Affibody AB

Life Science-podden: The perfect moment for an IPO

When is the right time to go for an IPO? What strategy is recommended in today´s rather uncertain business climate when it comes to taking your life science company public?

Aurevia

They’re all doing it – buying drug research

It is not easy to navigate the complex infrastructure for drug development in Sweden, where various contract players exist alongside the pharmaceutical companies.

Genes from Neanderthals can affect the correct drug dosage

A fifth of all Europeans carry gene variants inherited from Neanderthals, which cause certain drugs to break down more slowly. This may have implications for th...

RegSmart Life Science AB

Truly Labs AB

Svensk obesitaskandidat visade lovande resultat – ”Kan få stor betydelse”

Tabletten ska främja viktminskning utan att påverka aptit eller muskelmassa. Resultaten är lovande, enligt en klinisk fas I-studie från Karolinska institutet oc...

Artificial intelligence in radiology – “Risk prediction is very exciting”

A growing number of solutions based on artificial intelligence are being developed and used in healthcare. According to Sophia Zackrisson, Professor of Radiolog...

Så mycket väntas lecanemab sälja globalt

Försäljningen av Leqembi (lecanemab), som nyligen fick ett accelererat USA-godkännande som behandling mot Alzheimers sjukdom, väntas globalt uppgå till sju milj...

BioArctic moves forward with its candidate for Parkinson’s

BioArctic announces positive early phase study results for its drug candidate for Parkinson’s disease.

“I am driven by the desire to develop a product that can be sold worldwide”

Ranked number one in the world by the WHO in diarrhoea research and soon in phase III studies for its vaccine candidate – Scandinavian Biopharma is rushing forw...

Swedish and Ukrainian Medical Product Agencies sign an agreement

The Directors-General of the Swedish and Ukrainian Medical Products Agencies have signed a cooperation agreement.

MSD discontinues two Keytruda trials

MSD has stopped two late-stage trials that tested its blockbuster immunotherapy Keytruda as a treatment for skin and lung cancer.

Festo Expands its Portfolio with Multilayer Manifolds

Manufacturers of medical and laboratory equipment now receive solutions from a single source

Optimize Your Visibility

ZEISS presents our newest VersaXRM® 730 3D X-ray microscope.

Compact and leak-tight powerhouse

Media-separated solenoid valve VYKA from Festo is virtually leak-free

Anna Törner: ”Mom, do you think you’ll ever get married again?”

”I realize I’m slowly descending into that familiar statistical rabbit hole, where life’s biggest uncertainties are reduced to point estimates and confidence in...

Ny ordförande för Atlas Antibodies

Åsa Riisberg, styrelseproffs och tidigare partner i EQT, tar över ordförandeklubban i Atlas Antibodies.

RegFile AB

Studie: Upptäckt om tarmceller ger hopp om att bromsa Crohns sjukdom

Forskare vid Göteborgs universitet har upptäckt ett nytt sätt att angripa Crohns sjukdom. Det handlar om att reparera tarmcellernas skyddsbarriär för att behandla sjukdomen.

Sobi inleder nytt samarbete inom sepsis

Särläkemedelsbolaget Sobi inleder ett nytt forskningssamarbete och en klinisk studie kring en potentiell behandling vid sepsis.

Raised millions to develop a treatment for ´butterfly children´

Fragile as a butterfly’s wing – that’s how people living with Epidermolysis Bullosa are usually described. The Lund-based company Xinnate recently raised SEK 100 million in a new...

Standardisation in automation

B. Braun Melsungen had a great idea and implemented it throughout the plant. Production for infusion solutions was to be largely standardised. B. Braun hoped th...